News VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-06 pm EST			5-day change	1st Jan Change
0.5596 ^USD	+0.48%		-1.15%	-3.53%

Dec. 18	RTW Biotech Opportunities announces new investment in Yarrow Bioscience	RE
Dec. 17	VYNE Therapeutics Inc., Yarrow Bioscience, Inc. - M&A Call

Dec. 18	Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders	PR
Dec. 18	RTW Biotech Opportunities announces new investment in Yarrow Bioscience	RE
Dec. 17	$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)	PR
Dec. 17	VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders	BU
Dec. 17	VYNE Therapeutics Inc., Yarrow Bioscience, Inc. - M&A Call
Dec. 17	Yarrow Bioscience, Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire VYNE Therapeutics Inc. in a reverse merger transaction.	CI
Dec. 17	Vyne Therapeutics and Yarrow Bioscience announce merger agreement	RE
Dec. 17	VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement	AQ
Nov. 06	VYNE Therapeutics Q3 net loss narrows, strategic review ongoing	RE
Nov. 06	VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update	AQ
Nov. 06	VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-14	VYNE Therapeutics Inc. Announces Resignation of Christine Borowski as Member of the Board and as A Member of the Nominating and Corporate Governance Committee	CI
25-08-14	VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-14	VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update	AQ
25-08-14	VYNE Therapeutics : Repibresib Phase 2b Vitiligo Topline Results & Additional Analyses	PU
25-07-31	BTIG Research Downgrades VYNE Therapeutics to Neutral From Buy	MT
25-07-30	Sector Update: Health Care Stocks Decline in Late Afternoon Trading	MT
25-07-30	Sector Update: Health Care	MT
25-07-30	Top Midday Decliners	MT
25-07-30	VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo	CI
25-07-30	Vyne Therapeutics' Phase 2b Trial of Repibresib Gel in Nonsegmental Vitiligo Misses Primary Endpoint	MT
25-07-30	Vyne Therapeutics announces topline results from phase 2b trial with repibresib gel in nonsegmental vitiligo	RE
25-07-30	VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo	AQ
25-07-30	VYNE Therapeutics : Repibresib Phase 2b Vitiligo Topline Results	PU
25-07-02	VYNE Therapeutics Inc. Provides Program Update on Oral BET inhibitor VYN202	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Biotechnology & Medical Research

Filters